イチキ　ヨシノブ   ICHIKI Yoshinobu   市来　嘉伸    所属   埼玉医科大学  医学部 国際医療センター　呼吸器外科    職種   専任講師
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors.
掲載誌名	正式名：Journal of thoracic disease
巻・号・頁	11(4),1117-1123頁
著者・共著者	Yoshinobu Ichiki,Akihiro Taira,Yasuhiro Chikaishi,Hiroki Matsumiya,Masataka Mori,Masatoshi Kanayama,Yusuke Nabe,Shinji Shinohara,Taiji Kuwata,Masaru Takenaka,Soichi Oka,Ayako Hirai,Naoko Imanishi,Kazue Yoneda,Koji Kuroda,Yoshihisa Fujino,Fumihiro Tanaka
発行年月	2019/04
概要	Background: Although immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) have been established as one of standard therapy, the prognostic factors of ICIs remain unclear, aside from the programed cell death-ligand 1 (PD-L1) expression of tumor cells. The aim of this study was to determine the prognostic factors of ICIs. Methods: We analyzed the clinicopathological data of 44 cases of advanced NSCLC targeted with ICIs in our hospital, between February 2016 and February 2018, in order to determine the prognostic factors of ICIs. We also reviewed the literature regarding ICIs. Result: We retrospectively analyzed the 44 cases (26 nivolumab and 18 pembrolizumab cases). These patients were 38 men and 6 women, comprising 13 cases of adenocarcinoma, 29 squamous cell carcinoma and 2 unclassifiedtypes. Seven patients were using first-line therapy and while the others were using second-line therapy or later. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) mutations were negative in all the cases. The response rate and disease control rate were 20.5% and 51.3%, respectively. The median progression-free survival time and median surviv
DOI	10.21037/jtd.2019.04.41
PMID	31179053